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Abstract
Background: After coronary artery bypass grafting ischemia/reperfusion injury inducing cardiomyocyte apoptosis
may occur. This surgery-related inflammatory reaction appears to be of extreme complexity with regard to its
molecular, cellular and tissue mechanisms and many studies have been performed on animal models. However,
finding retrieved from animal studies were only partially confirmed in humans. To investigate this phenomenon
and to evaluate possible therapies in vitro, adequate human cardiomyocyte models are required. We established a
tissue model of human cardiomyocytes preserving the complex tissue environment. To our knowledge human
cardiac tissue has not been investigated in an experimental setup mimicking extracorporeal circulation just in
accordance to clinical routine, yet.
Methods: Cardiac biopsies were retrieved from the right auricle of patients undergoing elective coronary artery
bypass grafting before cardiopulmonary bypass. The extracorporeal circulation was simulated by submitting the
biopsies to varied conditions simulating cardioplegia (cp) and reperfusion (rep) in a microperfusion chamber. Cp/
rep time sets were 20/7, 40/13 and 60/20 min. For analyses of the calcium homoeostasis the fluorescent calcium
ion indicator FURA-2 and for apoptosis detection PARP-1 cleavage immunostaining were employed. Further the
anti-apoptotic effect of carvedilol [10 μM] was investigated by adding into the perfusate.
Results: Viable cardiomyocytes presented an intact calcium homoeostasis under physiologic conditions. Following
cardioplegia and reperfusion a time-dependent elevation of cytosolic calcium as a sign of disarrangement of the calcium
homoeostasis occurred. PARP-1 cleavage also showed a time-dependence whereas reperfusion had the highest impact
on apoptosis. Cardioplegia and carvedilol could reduce apoptosis significantly, lowering it between 60-70% (p < 0.05).
Conclusions: Our human cardiac preparation served as a reliable cellular model tool to study apoptosis in vitro.
Decisively cardiac tissue from the right auricle can be easily obtained at nearly every cardiac operation avoiding
biopsying of the myocardium or even experiments on animals.
The apoptotic damage induced by the ischemia/reperfusion stimulus could be significantly reduced by the cold
crystalloid cardioplegia. The additional treatment of cardiomyocytes with a non-selective b-blocker, carvedilol had
even a significantly higher reduction of apoptotis.
Introduction
Following extracorporeal circulation with cardioplegic
cardiac arrest and reperfusion death or apoptosis of car-
diomyocytes may occur [1,2]. Apoptosis is the ultimate
result of convergence of multiple signaling pathways
triggered by events such as nutrient and oxygen
deprivation, intracellular calcium overload and excessive
reactive oxygen species production [3]. In the setting of
cardiac surgery these events can finally result in con-
tractile dysfunction of the myocardium [4] and atrial
fibrillation [5]. Apoptosis of cardiac non-myocytes also
contributes to maladaptive remodelling and the transi-
tion to decompensated congestive heart failure [6].
Regarding this potentially impact of apoptosis on clini-
cal outcomes, there is a demand for therapeutical
strategies.
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This surgery-related inflammatory reaction appears to
be of extreme complexity with regard to its molecular,
cellular and tissue mechanisms and many studies have
been performed on animal models [7-9]. However, find-
ing retrieved from animal studies were only partially
confirmed in humans. To study the comparability with
human tissue, we established an in vitro model using
human cardiac tissue preserving the complex tissue
milieu of the myocytes.
Materials and methods
Ethics declaration
The investigation conforms with the principles outlined
in the Declaration of Helsinki. In addition, approval was
granted by the Ethics Committee of the Faculty of Med-
icine of the Eberhard-Karls-University of Tübingen, Ger-
many (approval reference number 183/2002 V).
Patient characteristics
60 patients undergoing elective coronary artery bypass
grafting were included in this study and gave informed
consent before study entry. The mean age of the
patients was 57 ± 6 (mean ± SEM), 58% of the patients
were female.
Cardiac tissue
Human tissue was retrieved from the auricle of the right
atrium of patients before cardiopulmonary bypass and
was processed immediately. Each biopsy was trans-
muraly divided with a scalpel in about 8 to 10 cubic
pieces measuring approximately 500 μm. Cardiac speci-
mens were randomly determined for incubation (incuba-
tion time 30 min) with the fluorescent dye FURA 2-AM
for calcium analyses or for studies on apoptosis
(described in the following sections). Cardiac specimens
were outside the body before being mounted and tested
in the chamber system for a maximum of 45 min, but
during the incubation time the oxygen supply was main-
tained continuously.
Chemicals and buffer solutions
The modified Krebs-Henseleit buffer (KH) consisted of
115 mM NaCl, 4.5 mM KCl, 1.18 mM MgCl2, 1.25 mM
CaCl2, 1.23 mM NaH2PO4, 1.19 mM Na2SO4, 80 mM
glucose, and 10 mM HEPES, pH adjusted to 7.4 at 37°C
with NaOH. The Ca-free medium was the standard
medium lacking CaCl2 and containing 0.5 mM EGTA.
Cardioplegic solution
The cardioplegic solution was prepared on the basis of
Ca-free Krebs-Henseleit buffer (KH) consisting of 115
mM NaCl, 4.5 mM KCl, 1.18 mM MgCl2, 0.5 mM
EGTA, 1.23 mM NaH2PO4, 1.19 mM Na2SO4, 80 mM
glucose, and 10 mM HEPES, pH adjusted to 7.4 at 37°C
with NaOH.
For cardioplegia a solution containing 60 mmol K+
was added in a 1:4 proportion to the Ca-free KH buffer,
which was administered at 4°C, in analogy to blood
cardioplegia regimen [10]. The resulting K+ concentra-
tion in this mixture was 16.5 mM.
Cell viability
The viability of cardiomyocytes was assessed by trypan
blue exclusion before each experiment under a Nikon
Labophot Y-2A epiflurescence microscope and a Nikon
×20 long-distance objective (Cf Plan ELWD, Nikon,
Nippon Kokagu K.K., Tokyo, Japan). Only cardiac speci-
mens consisting of ≥ 99% viable cardiomyocytes in the
centre were included. Due to the preparation the sec-
tion margins (cutting edges) of the cardiac specimens
contained 5-10% non-viable cardiomyocytes. Therefore
only central parts of the cardiac specimens were
analyzed.
Microperfusion chamber with physical adhesion of the
cardiac specimens
Our self developed microperfusion chamber consisted of
three components (Figure 1). A temperature-controlled
plexiglas block was mounted on a metal sheet to allow
fixation on the stage of a microscope. In the middle of
this plexiglas block, a square, the size and depth of a
coverglass, was cut out for insertion of a coverglass. The
second component was mounted over the first, and con-
sisted of another plexiglas block, however, with a rhom-
boid hole in the middle. In this free rhomboid chamber,
a nylon net with a pore size of 400 μm was mounted
diagonally. To enable perfusion of the rhomboid cham-
ber, a thin pipe was introduced at one end of the block,
entered the chamber and exited at the other end. This
block was covered with a thin metal sheet with a cover-
glass in the middle of the sheet. A thin watertight sili-
con layer between each component sealed the
microperfusion chamber.
The probe was fixed physically at the nylon net by the
laminar flow of the hydrostatic perfusion system
through the chamber. With a perfusion velocity of 5 ml/
min, the probe was fixed to the net in a stable position,
because of the laminar flow.
Figure 1 Microperfusion chamber. A: Top and B: Base Plexiglas
components. Inlet pipe (1), Plexiglas block (2), rhomboid shaped
chamber (3), cardiac tissue (4), nylon net (5) and outlet pipe (6). The
top and base Plexiglas components were fastened with 4 screws.
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Cardiomyocyte imaging
Calcium measurements were performed by digital ima-
ging epifluorescence microscopy (Hamamatsu Photonics,
Japan). A Nikon Labophot Y-2A epiflurescence micro-
scope and a Nikon ×20 long-distance objective (Cf Plan
ELWD, Nikon, Nippon Kokagu K.K., Tokyo, Japan)
were used. Cardiac specimens were excited with a
xenon arc lamp, and the emitted light was detected with
a charge-coupled device camera (CCD camera). Image
analysis was performed with the Hamamatsu Argus 50
system on a personal computer.
Ratio imaging with FURA-2
FURA-2 is a Ca2+ indicator. The AM ester is cleaved
and hydrolyzed by non-specific esterases, resulting in
the polyanionic indicator FURA-2, which leaks out of
the cells far more slowly than its parent compound.
This highly selective substance for calcium is nearly
insensitive to slight fluctuations in the physiological
range of the pH value. Fluorescence images of FURA-2
loaded cardiac specimens were obtained at excitation
wavelengths of 340 nm and 380 nm, with an emission
wavelength of 510 nm. Via FURA-2 the intracellular cal-
cium concentration can be displayed by using ratio
values 340/380. Ratio imaging [11] minimizes a number
of negative effects which occur and disturb measure-
ments like uneven dye loading, leakage of FURA-2 and
bleaching. Background fluorescence determined in each
experiment constituted to less than 5% of the fluores-
cence signal and therefore was subtracted from the
intensities obtained at 340 and 380 nm.
FURA-2 AM loading
Cardiac specimens were incubated with the fluorescent
dye FURA-2 AM [100 μmol/l] (Molecular Probes,
Eugene, OR, USA) for 30 min in 35°C KH (gassed with
carbogen (95% O2 and 5% CO2)). Meanwhile the other
half of the cardiac specimens were kept separately in 35°
C KH (gassed with carbogen). At the end of the incuba-
tion the incubated and non-incubated cardiac specimens
were transferred in 2 separate microperfusion chambers.
After that the later decribed experimental protocol was
carried out for both cardiac specimens simultaneously.
The microperfusion chambers were arranged parallely
so that same conditions like perfusion velocity, tempera-
ture and perfusion times were guaranteed.
Calcium homoeostasis
For evaluation of the impact on the calcium homoeostasis
in the cardiomyocytes the initial and final calcium ratio
values had to be analyzed. This was defined as Δ-ratio;
Δ-ratio = ratiofinal-ratioinitial. Significant (p < 0.05) differ-
ences between both values were interpreted as calcium
overload as a sign of disarranged calcium homoeostasis.
Effect of carvedilol on apoptosis
Carvedilol is a nonspecific blocker that inhibits both b1-
and b2-adrenergic receptors and furthermore is a strong
antioxidant with antiapoptotic capacity [12]. To test
whether treatment with a nonspecific b-blocker
decreases apoptosis, we treated the cardiac specimens
continuously with carvedilol. The administered concen-
tration of carvedilol was 10 μmol/l. The cardiac speci-
mens were subjected to various periods of cardioplegia
(20, 40 or 60 min) followed by 1/3 of the chosen cardio-
plegia time as reperfusion (7, 13 or 20 min).
Immunohistochemistry
The slides with the cryosections of the samples (10 μm)
were processed prior to the staining according to the
manufacturer’s recommendation (Epitomics, Inc., Bur-
lingame, CA, USA). The described chemicals were pur-
chased from Biochrom, Berlin Germany. In brief, the
cryosections were immersed into the staining dish con-
taining the antigen retrieval solution: 9 ml of stock solu-
tion A (0.1 M citric acid solution) and 41 ml of stock
solution B (0.1 M sodium citrate solution) were added
to 450 ml of destillated H2O and adjusted to pH 6.0.
After warming for 30 min in a rice cooker and cooling
down the slides were washed with TBST (Tris-Buffered
Saline and 0.1% Tween 20) for 5 min on a shaker. For
the inactivation of endogenous peroxidases the slides
were covered with 3% hydrogen peroxide for 10 min
and later washed with TBST. After that the slides were
immersed into the blocking solution (PBS (Dulbecco’s
Phosphate Buffered Salts) and 10% bovine serum albu-
min) for 1 hour.
Later the cryosections were incubated overnight in a
humidified chamber (4°C) with antibodies against
PARP-1 (Anti-Poly-(ADP-Ribose)-Polymerase)-cleavage
(Epitomics, Inc., Burlingame, CA, USA). PARP is a zinc-
dependent DNA binding protein that recognizes DNA
strand breaks and is presumed to play a role in DNA
repair. PARP is cleaved in vivo by caspase-3 [13]. The
antibody only recognizes the p25 cleaved-form of
PARP-1.
Later for detection to each section secondary HRP-
conjugated anti-rabbit antibody (Epitomics, Inc., Burlin-
game, CA, USA) diluted in the blocking solution per
manufacturer’s recommendation was applied and incu-
bated for 1 hour at room temperature.
The number of cells on the cryosections was deter-
mined by counting the nuclei of cardiomyocytes after
staining with DAPI (4’,6-Diamidino-2-phenylindole 2
HCl), a dye known to form fluorescent complexes with
natural double-stranded DNA, under a fluorescence
microscope (Zeiss, Jena, Germany). In each analysis
three different areas of the cryosections were counted
using 40-fold magnification. Fluorescence images (blue)
of DAPI loaded cardiac specimens were obtained at an
excitation wavelength of 360 nm, with an emission
wavelength of 460 nm. DAPI was purchased from
Sigma-Aldrich, Germany.
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Experimental protocol
The protocol was designed to simulate our clinical rou-
tine with the single difference that our cardioplegic solu-
tion with the same potassium concentration (16.5
mmol/l) and temperature (4°C) did not contain blood,
but the Ca-free KH-buffer.
The 4 different groups (I-IV) were arranged as follows:
cardioplegia (I) with or without reperfusion (II). The
control groups receiving no cardioplegia were subjected
to ischemia (III) with or without reperfusion (IV). All
cardiac specimens had been prior incubated with the
fluorescent dye FURA 2-AM for simultaneous calcium
analyses. Each experiment, group (I-IV), was carried out
with the specimens of one patient, i.e. specimens of
patients were analyzed separately.
The cardiac specimens were initially equilibrated with
KH for 5 min (32°C and gassed with carbogen. After
that the cardioplegic solution (4°C) was administered for
5 min. For induction of apoptosis the cardiac specimens
were subjected to various periods of cardioplegia (20, 40
or 60 min). During the cardioplegia period the perfusion
of the microperfusion chamber was stopped, so that the
oxygen supply was discontinued. Later reperfusion was
initiated and it’s duration was defined as being 1/3 of
the chosen cardioplegia time (7, 13 or 20 min) just in
analogy to our surgical routine. Reperfusion was modi-
fied so that initially for 2 min the cardiac specimens
were reperfused with 35°C Ca-free KH and until the rest
with 35°C KH. Otherwise the addition of calcium at this
time would interfere with the calcium homoeostasis in
the cardiomyocytes. So that discrimination between Ca-
uptake induced fluorescence signal increase and reperfu-
sion induced one would had been impossible.
Finally, the cardiac specimens were snap-frozen in
liquid nitrogen.
Statistical Analysis
Analysis of calcium recordings and graphics were per-
formed using Sigma Plot software (version 9.0, SPSS
Inc., Chicago, IL). Data are expressed as the mean ±
standard error of mean (SEM) and statistical analysis
was performed using the JMP software package (version
7.0, SAS Institute, Cary, NC, USA) employing multi-fac-
torial analyses of variance tests (ANOVA) with Tukey’s




In the cardiac specimens treated with cardioplegia and
reperfusion no significant (p < 0.05) cytosolic calcium
increase and homoeostasis disarrangement could be
detected (Table 1 and Figure 2, 3 and 4).
In the control groups with non-cardioplegia and
reperfusion ratiofinal was significantly (p < 0.05) higher
than the ratioinitial values, resulting in elevated Δ-ratio
values correlating positively with the duration of ische-
mia and reperfusion times (Table 1 and Figures 2, 3 and
4).
PARP-1 stained cardiomyocytes
Apoptotic cardiomyocytes could be reliably distin-
guished of non-apoptotic ones. A bright nuclear stain-
ing, sometimes featuring granular structures was
indicative for PARP-1 cleavage (Figure 5).
The impact of cardioplegia on apoptosis
The mean total cardiomyocyte number in 3 analyzed
central areas on the cryosections was 300 ± 25 (mean ±
SEM). Usually the cryosections revealed around 21 ± 11
smaller or destructed nuclei, which were excluded.
In general cardiomyocytes featured increasing PARP-1
expression depending on the duration of the ischemia
and reperfusion period, just like in cardiomyocytes sub-
jected to cardioplegia and reperfusion. The longer the
cardioplegia and reperfusion periods lasted the higher
was the number of PARP-1 positive or apoptotic cardio-
myocytes. As presented in figure 6 cardioplegia could
significantly (p < 0.05) reduce apoptosis compared to
cardiomyocytes not subjected to cardioplegia.
Effect of carvedilol on apoptotis
The longer the cardioplegia and reperfusion period
lasted the higher was the percentage of PARP-1 cleavage
positive or apoptotic cardiomyocytes. In contrast to
non-treated cardiac specimens, sections prepared from
Table 1 Representing the effect of cardioplegia on calcium homoeostasis.
Group Cp/rep in min Ratio initial Ratio final Δ-ratio Ratiofinal-
ratioinitial
n =
Control, non-cp + rep 20/7 1.59 ± 0.04 1.65 ± 0.02 0.06 * 5
Control, non-cp + rep 40/13 1.68 ± 0.02 1.83 ± 0.02 0.12 * 5
Control, non-cp + rep 60/20 1.52 ± 0.01 1.64 ± 0.05 0.12 * 5
Cp + rep 20/7 1.57 ± 0.01 1.58 ± 0.01 0.01 5
Cp + rep 40/13 1.56 ± 0.02 1.56 ± 0.01 0 5
Cp + rep 60/20 1.60 ± 0.01 1.62 ± 0.01 0.02 5
Experimental protocol comparing calcium homoeostasis in the control group (non-cardioplegia and reperfusion) versus the cardioplegia and reperfusion group.
Time sets were 20/7, 40/13 and 60/20 min. Δ-ratio was calculated as ratiofinal-ratioinitial. Ratio values of n = 5 experiments are noted as mean ± SEM. Significant (p
< 0.05) calcium homoeostasis disarrangements were detected in the control group (marked with stars).
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cardiac specimens treated with carvedilol showed a sig-
nificant (p < 0.05) reduction of PARP-1 cleavage positive
cardiomyocytes (Figure 5).
Discussion
In the present study our first goal was to apply cardio-
plegia and reperfusion just in accordance to our clinical
routine to administer cardioplegia and reperfusion to
simulate the extracorporeal circulation in our experi-
mental model. Our second goal was to induce and
detect apoptosis and concomitant alterations of the cal-
cium homoeostasis in vitro in the presented experimen-
tal setup. Our third goal was to analyse the
antiapoptotic properties of the non-selective b-blocker
carvedilol. In our experimental model human cardio-
myocytes were kept in their natural environment as
intact cardiac tissue. Otherwise human papillary muscle
could be employed but obtaining it before cardioplegic
arrest is not an imaginable and feasible option during
clinical routine. The simulation of ischemia in isolated
cardiomyocyte models can provide important insights
into the pathophysiology of myocardial ischemic injury
and its underlying molecular mechanisms as was the
subject in previous studies in isolated mammalian cardi-
omyocytes [7], isolated papillary muscle preparations [8]
or animal heart models [9]. The distinctive difference of
our study was to demonstrate our experimental set up
utilizing the human atrial cardiac tissue model for apop-
tosis studies inducing apoptotis just in accordance to
our clinical routine with cardioplegia and reperfusion
without induction of simulated ischemia with N2 perfu-
sion like in previous studies [14]. Like presented above
the cardioplegia and reperfusion stimulus proved to be
an adequate stimulus for apoptosis induction and is
comparable with those in the literature [15,16].
Isolated cardiomyocyte models of simulated ischemia
provided much insight into the pathophysiology of myo-
cardial ischemic injury [17]. The use of isolated adult
mammalian cardiomyocyte models can serve to discover
underlying mechanisms occurring during ischemia
Figure 2 Calcium homoeostasis was intact in the cardioplegia
group. In the control group (ischemia without cardioplegia) final
calcium ratio values were significantly (p < 0.05) elevated. Ratio
values are plotted as mean ± SEM of n = 5 experiments. Cp:
cardioplegia for 5 min.
Figure 3 Calcium homoeostasis was intact in the cardioplegia
group. In the control group (ischemia without cardioplegia) final
calcium ratio values were significantly (p < 0.05) elevated. Ratio
values are plotted as mean ± SEM of n = 5 experiments. Cp:
cardioplegia for 5 min.
Figure 4 Calcium homoeostasis was intact in the cardioplegia
group. In the control group (ischemia without cardioplegia) final
calcium ratio values were significantly (p < 0.05) elevated. Ratio
values are plotted as mean ± SEM of n = 5 experiments. Cp:
cardioplegia for 5 min.
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versus those resulting from reperfusion. Results from
several studies [18,19], however, indicate that reperfu-
sion after myocardial ischemia can result in exacerbation
of injury and apoptosis. Apoptosis is an important
mechanism of active cellular death that is distinct from
necrosis and has been implicated in the pathogenesis of
a variety of degenerative and ischemic human diseases.
In fact, several studies suggest that apoptosis is a reper-
fusion-related phenomenon [20]. Most of the studies
were performed on isolated mammalian cardiomyocytes
[21] or on isolated papillary muscle preparations [22]
whereas the fewer human preparations were supposed
to reflect the situation in the original enviroment better
[23]. These techniques detect apoptosis at a very late
stage, however for a better understanding of therapeuti-
cal manipulations earlier stages are warranted [24]. In
the present study the usefullness of our atrial cardiac
tissue model for apoptosis studies should be demon-
strated. The atrial tissue is easily obtainable from
patients undergoing open-heart surgery, it is simple to
prepare, the procedure is inexpensive and human
cardiac tissue is supposed to represent the original cellu-
lar environment better. Another advantage of the atrial
tissue is that due to its morphology with a thin wall
nutrition in vivo is mainly provided by diffusion.
In the present study human cardiomyocytes preserved
in the natural cellular formation as atrial tissue prepara-
tion were submitted to varied cardioplegic-ischemia and
reperfusion according to our routine cardioplegia regi-
men. The impact on apoptosis was investigated selec-
tively after ischemia or reperfusion analysing cytosolic
calcium changes and indicators for caspase-3 activation
with resulting PARP cleavage. Viable, non-apoptotic car-
diomyocytes were capable to maintain the essential cal-
cium homoeostasis preventing a calcium overload. This
was negatively influenced by longer duration of cardio-
plegia and reperfusion. One possible explanation for that
could be uncontrolled calcium uptake per diffusion and
release of the sarcoplasmatic reticulum. Hallmarks of
apoptosis include morphological alterations such as cell
shrinkage, membrane blebbing, chromatin condensation,
and DNA fragmentation [15]. In contrast to that many
Figure 5 Representative grayscaled fluorescent images of cardiomyocytes treated with cardioplegia and reperfusion (control group,
first column) versus the same treatment plus the addition of carvedilol (second column). After DAPI counterstaining the greater nuclei of
cardiomyocytes allow their distinction from fibroblasts with smaller nuclei. In PARP-1 cleavage positive, apoptotic cardiomyocytes nuclei feature
an intensive granular fluorescence intensity (arrows). The exemplary images represent one experiment with the according cardioplegia and
reperfusion time set noted on the left side. During the cryosection procedure artifacts presenting as nuclei conglomerates could not be avoided;
these were excluded from analyses.
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apoptosis studies administered ischemia and reperfusion
lasting many hours. If these experimental protocols were
applied during routine cardiac surgery the result would
be deleterious for the patients. As an indicator of initia-
tion of apoptosis signal-pathways with resulting caspase
activation [25] PARP cleavage was detectable in every
experiment although reports about missing PARP clea-
vage exist [26]. For a definite statement further investiga-
tions especially on cardiomyocytes are necessary.
In our presented study the ischemia/reperfusion stimu-
lus proved to be an adequate stimulus for apoptosis
induction. Moreover, our results about the cardiomyocte
apoptosis after an ischemia/reperfusion stimulus are
comparable to those presented in the literature [15]. The
partial inhibition of apoptosis by carvedilol as observed
in our study has also been previously described in an ani-
mal model of end-stage heart failure [27,28]. A recent
study could demonstrate that the cardioprotective effect
of carvedilol against ischemia and/or reperfusion injury is
via adenosine-dependent mechanisms [29]. The reason
for partial suppression of apoptosis in the carvedilol
treatment group in our study could also be dose related
as being described in previous studies [30]. Carvedilol
treatment inhibited apoptotis in a way that longer dura-
tion of cardioplegia and reperfusion had no significant
increase of the apoptotis rate, whereas without carvedilol
the apoptosis rate increased. The high apoptosis rate in
the control group especially after 60 min cardioplegia
and 20 min reperfusion should not be extrapolated into
the in vivo situation without any caution as atrial and
ventricular myocardium possess specific characteristics
that may influence the susceptibility to ischaemia/reper-
fusion injury. One explanation is the reported difference
in the distribution of potassium channels [31], which
contribute to the characteristic differences between atrial
and ventricular action potentials and may determine a
different response to cardioplegia/reperfusion. Another
explanation is that our experimental setup is distinctive
of our surgical routine as we do not tolerate cardioplegia
longer than 20 min and therefore apply cardioplegia in
20 min intervals. On the other hand even it is well
known that carvedilol ameliorates cardiac ischaemic tis-
sue injury [32], its antioxidant effects have not, to our
knowledge, been reported in an experimental setup
mimicking extracorporeal circulation, yet.
Conclusions of the present study are that our atrial
tissue model is a reliable tool to investigate apoptosis in
vitro. Decisively cardiac tissue from the right auricle can
be easily obtained at nearly every cardiac operation
avoiding biopsying of the myocardium or even experi-
ments on animals. The ischemia/reperfusion stimulus
induced apoptosis in cardiomyocytes depending on the
duration of the stimulus. Apoptotic cardiomyocytes fea-
tured alterations of their calcium homeostatis resulting
in a calcium overload. At the same time the apoptotic
damage induced by the ischemia/reperfusion stimulus
could be significantly reduced by the cold crystalloid
cardioplegia. The additional treatment of cardiomyo-
cytes with a non-selective b-blocker, carvedilol had even
a significantly higher reduction of apoptotis.
Finally the relatively short cardioplegic-ischemia and
reperfusion periods could be interpreted as limitation of
the present study. Our future perspectives are to widen
the research on other drugs with potential anti-apopto-
tic effect. Another limitation is that in this study only a
single concentration of carvedilol was employed. There-
fore, detailed dose-response relationships of carvedilol
on apoptotic events have not been investigated. Never-
theless, with the concentration employed in this study,
apoptotic events could be inhibited considerably.
Furthermore the primary purpose of this study was to
test the principle of b-blockade on apoptotic events
rather than to study dose-response relationships. How-
ever, our results indicate a definite beneficial effect of
carvedilol on apoptotic events at least in vitro.
Figure 6 Antiapoptotic effect of cardioplegia versus ischemia.
The x-axis represents time in min and the y-axis the number of
PARP-1 cleavage positive, apoptotic cardiomyocytes. There is a time-
dependent significant (p < 0.05) increase of apoptotic
cardiomyocytes after reperfusion. Further there is a significant (p <
0.05) reduction of apoptosis in cardiomyocytes treated with
cardioplegia versus ischemia. One column represents data of n = 5
experiments, noted as mean ± SEM. Stars mark the significances
between the compared columns. The mean total cardiomyocyte
number in 3 analyzed central areas on the cryosections was 300 ±
25 (mean ± SEM).
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